Abstract Details

Title Integrating Biomarkers for Real-time Risk Assessment and Outcome Prediction in Traumatic Brain Injury Management

Topic Neuro Trauma and Critical Care

Presentation(s) P6 - Poster Session 6 (11:45 AM-12:45 PM)

Poster/Presentation
Number 7-010

Objective

1. To assess the correlation between the normalization time of biomarkers (S100B and NSE) and recovery time as well as clinical outcomes in TBI patients.

2. To develop and validate a biomarker-driven real-time risk stratification system using S100B and NSE normalization times to enhance ICP management and improve clinical outcomes in TBI patients.

Background Traumatic brain injury (TBI) is a leading cause of death and disabilities. Intracranial pressure (ICP) monitoring and clinical scoring remain the gold standard for treating TBI. Biomarkers such as neuron-specific enolase (NSE) and S100B have shown prognostic value in TBI. However, their potential for real-time risk stratification and personalized treatment is still under research.

Design/Methods

This study reviewed 100 TBI patients, stratified by how quickly their biomarkers normalized:

• Low-risk: within 7 days

• Moderate-risk: 7–10 days

• High-risk: more than 10 days

We evaluated clinical outcomes, including recovery time, ICU stay, and Glasgow Outcome Scale (GOS) scores.

Results The mean biomarker normalization time was 8.3 days (SD ± 3.2). A significant inverse correlation between normalization time and recovery duration (r = -0.65, p < 0.01) was observed. Patients normalizing within 7 days had favorable outcomes (GOS 4–5) more frequently (80% vs. 50%, p < 0.05). The AUC for predicting favorable outcomes was 0.78 (95% CI 0.68–0.87).

Low-risk patients (35%) had a 5-day ICU stay with no mortality. Moderate-risk patients (40%) required 10 days of ICU stay, with a 5% mortality rate. High-risk patients (25%) needed aggressive interventions, with an ICU stay of 15 days and a 20% mortality rate.

Conclusions

Biomarker normalization times is a novel approach for stratifying TBI patients into real-time risk categories, allowing for more tailored treatment strategies and potentially improving clinical outcomes. Shorter normalization times are associated with better outcomes and faster recovery, supporting the utility of biomarkers in optimizing personalized treatment. The biomarker-based risk stratification model offers a novel method for improving ICP management and enhancing clinical outcomes in TBI patients.

Authors/Disclosures
Apurva H. Patel, MD PRESENTER	Dr. Patel has nothing to disclose.
Sweta Sahu	Dr. Sahu has nothing to disclose.
Pranay Marlecha	Dr. Marlecha has nothing to disclose.
Tirath Patel, MD	Mr. Patel has nothing to disclose.
Bharathi Gadad, PhD	Dr. Gadad has nothing to disclose.
Nikhilesh Anand, MD	Dr. Anand has nothing to disclose.

��ɫ��

��ɫ��